Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04058756
Title Rollover Study for Continued Safety and Tolerability in Subjects Treated With Spartalizumab Alone or in Combination With Other Study Treatments
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | POL | NLD | ITA | HUN | FRA | ESP | DEU | CZE | CHE | CAN | BEL

Facility Status City State Zip Country Details
Columbia University Medical Center New York New York 10032 United States Details
Providence Portland Medical Center Portland Oregon 97123 United States Details
MD Anderson Cancer Center Uni of Te Houston Texas 77030 United States Details
Novartis Investigative Site Leuven 3000 Belgium Details
Novartis Investigative Site Liege 4000 Belgium Details
Novartis Investigative Site Toronto Ontario M5G 2M9 Canada Details
Novartis Investigative Site Montreal Quebec H3T 1E2 Canada Details
Novartis Investigative Site Guangzhou Guangdong 510515 China Details
Novartis Investigative Site Guangzhou 510060 China Details
Novartis Investigative Site Brno Czech Republic 656 53 Czechia Details
Novartis Investigative Site Lille 59037 France Details
Novartis Investigative Site Lyon 69373 France Details
Novartis Investigative Site Marseille 13273 France Details
Novartis Investigative Site Marseille 13885 France Details
Novartis Investigative Site Villejuif 94800 France Details
Novartis Investigative Site Essen 45147 Germany Details
Novartis Investigative Site Heidelberg 69120 Germany Details
Novartis Investigative Site Jena 07740 Germany Details
Novartis Investigative Site Ulm 89081 Germany Details
Novartis Investigative Site High West Hong Kong Details
Novartis Investigative Site Pokfulam Hong Kong Details
Novartis Investigative Site Shatin HONGKONG Hong Kong Details
Novartis Investigative Site Budapest H 1122 Hungary Details
Novartis Investigative Site Debrecen 4032 Hungary Details
Novartis Investigative Site Milano MI 20132 Italy Details
Novartis Investigative Site Milano MI 20133 Italy Details
Novartis Investigative Site Milano MI 20141 Italy Details
Novartis Investigative Site Rozzano MI 20089 Italy Details
Novartis Investigative Site Modena MO 41124 Italy Details
Novartis Investigative Site Aviano PN 33081 Italy Details
Novartis Investigative Site Siena SI 53100 Italy Details
Novartis Investigative Site Napoli 80131 Italy Details
Novartis Investigative Site Seoul 03080 Korea, Republic of Details
Novartis Investigative Site Seoul 05505 Korea, Republic of Details
Novartis Investigative Site Leiden Zuid Holland 2333 ZA Netherlands Details
Novartis Investigative Site Gdansk 80 952 Poland Details
Novartis Investigative Site Poznan 60-693 Poland Details
Novartis Investigative Site Barcelona Catalunya 08035 Spain Details
Novartis Investigative Site Barcelona Catalunya 08036 Spain Details
Novartis Investigative Site Hospitalet de LLobregat Catalunya 08907 Spain Details
Novartis Investigative Site Valencia Comunidad Valenciana 46010 Spain Details
Novartis Investigative Site Madrid 28009 Spain Details
Novartis Investigative Site Madrid 28034 Spain Details
Novartis Investigative Site Zuerich 8091 Switzerland Details
Novartis Investigative Site Taipei 10002 Taiwan Details
Novartis Investigative Site Songkhla Hat Yai 90110 Thailand Details
Novartis Investigative Site Bangkok 10310 Thailand Details
Novartis Investigative Site Chiang Mai 50200 Thailand Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field